ES2098273T3 - Diagnostico y tratamiento de los trastornos neuro-cognitivos asociados a una disfuncion inmunologica sistemica. - Google Patents

Diagnostico y tratamiento de los trastornos neuro-cognitivos asociados a una disfuncion inmunologica sistemica.

Info

Publication number
ES2098273T3
ES2098273T3 ES90914995T ES90914995T ES2098273T3 ES 2098273 T3 ES2098273 T3 ES 2098273T3 ES 90914995 T ES90914995 T ES 90914995T ES 90914995 T ES90914995 T ES 90914995T ES 2098273 T3 ES2098273 T3 ES 2098273T3
Authority
ES
Spain
Prior art keywords
neuro
disorders associated
cognitive disorders
systemic immunological
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90914995T
Other languages
English (en)
Inventor
William A Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEM Pharmaceuticals Corp
Original Assignee
HEM Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HEM Pharmaceuticals Corp filed Critical HEM Pharmaceuticals Corp
Application granted granted Critical
Publication of ES2098273T3 publication Critical patent/ES2098273T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LAS ENFERMEDADES NEUROCOGNITIVAS DEL TIPO ASOCIADO CON FUNCIONAMIENTOS DEFECTUOSOS SISTEMATICOS DEL SISTEMA INMUNOLOGICO SE DIAGNOSTICAN Y SE DISTINGUEN DE LAS ENFERMEDADES SICOLOGICAS O NEUROSIQUIATRICAS QUE PRESENTAN SINTOMAS CLINICOS SIMILARES. SE DESCRIBE TAMBIEN LA INTERVENCION TERAPEUTICA CON DS ARNS.
ES90914995T 1989-10-16 1990-10-09 Diagnostico y tratamiento de los trastornos neuro-cognitivos asociados a una disfuncion inmunologica sistemica. Expired - Lifetime ES2098273T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42159689A 1989-10-16 1989-10-16
US50418590A 1990-04-04 1990-04-04

Publications (1)

Publication Number Publication Date
ES2098273T3 true ES2098273T3 (es) 1997-05-01

Family

ID=27025302

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90914995T Expired - Lifetime ES2098273T3 (es) 1989-10-16 1990-10-09 Diagnostico y tratamiento de los trastornos neuro-cognitivos asociados a una disfuncion inmunologica sistemica.

Country Status (14)

Country Link
US (1) US5958718A (es)
EP (1) EP0495831B1 (es)
JP (2) JP3256222B2 (es)
CN (1) CN1053360A (es)
AT (1) ATE147629T1 (es)
AU (1) AU647754B2 (es)
BR (1) BR9007757A (es)
DE (1) DE69029737T2 (es)
ES (1) ES2098273T3 (es)
HU (1) HUT65370A (es)
IE (1) IE903681A1 (es)
NZ (1) NZ235656A (es)
PT (1) PT95601B (es)
WO (1) WO1991005559A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE152623T1 (de) * 1986-12-17 1997-05-15 Glaxo Group Ltd Verwendung von heterozyklischen derivaten zur herstellung von arzneimitteln
EP0492020A1 (en) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds for treating cognitive disorders
AU2554792A (en) * 1991-09-26 1993-04-27 Hem Pharmaceuticals Corp. Method of neutralizing il-1 using dsrnas
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
MA54874A (fr) * 2019-02-01 2021-12-08 Avrobio Inc Compositions et procédés de traitement des troubles neurocognitifs
CN115595315A (zh) * 2021-06-28 2023-01-13 四川大学华西医院（Cn） 核糖核酸酶i在抑制疼痛的药物中的新用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113162B1 (en) * 1982-09-16 1989-07-19 Hem Research, Inc. Anti-proliferative action of dsnras on tumor cells
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
IE72103B1 (en) * 1987-08-12 1997-03-12 Hem Res Inc Promotion of host defense by systemic dsRNA treatment
EP0306347B1 (en) * 1987-09-04 1995-05-10 Hem Pharmaceuticals Corp. Diagnosis of double-stranded RNA deficiency states
EP0350151B1 (en) * 1988-07-07 1994-03-30 Hem Pharmaceuticals Corp. Diagnosing and treating chronic fatigue syndrome

Also Published As

Publication number Publication date
DE69029737T2 (de) 1997-06-19
PT95601A (pt) 1991-09-13
HUT65370A (en) 1994-05-02
CN1053360A (zh) 1991-07-31
NZ235656A (en) 1997-07-27
EP0495831A4 (en) 1992-10-21
DE69029737D1 (de) 1997-02-27
US5958718A (en) 1999-09-28
HU9201196D0 (en) 1992-08-28
WO1991005559A1 (en) 1991-05-02
JPH05501199A (ja) 1993-03-11
AU647754B2 (en) 1994-03-31
AU6523390A (en) 1991-05-16
JP3177233B2 (ja) 2001-06-18
ATE147629T1 (de) 1997-02-15
BR9007757A (pt) 1992-08-11
IE903681A1 (en) 1991-04-24
PT95601B (pt) 1997-08-29
EP0495831B1 (en) 1997-01-15
EP0495831A1 (en) 1992-07-29
JP2000125899A (ja) 2000-05-09
JP3256222B2 (ja) 2002-02-12

Similar Documents

Publication Publication Date Title
Miller et al. The release of PGE2-like activity into aqueous humor after paracentesis and its prevention by aspirin
Cameron et al. St. Anthony's fire rekindled: gangrene due to therapeutic dose of ergotamine
Ichikawa et al. Capsular ataxic hemiparesis: a case report
ES2098273T3 (es) Diagnostico y tratamiento de los trastornos neuro-cognitivos asociados a una disfuncion inmunologica sistemica.
AL‐ABOOSI et al. Behcet's disease: clinical study of Jordanian patients
Murphy et al. Persisting cholinergic erythema: a variant of cholinergic urticaria
ATE103493T1 (de) Diagnose und behandlung chronischer ermuedungserscheinungen.
Raftery et al. INFECTIOUS MONONUCLEOSIS AND GUILLAIN-BARRÉ SYNDROME: Report of Three Cases
Aviram Henoch-Schönlein syndrome associated with quinidine
Bartfai et al. Effect of sulpiride on vigilance in healthy subjects
Mooradian et al. Biweekly intracavernous administration of papaverine for erectile dysfunction.
Maclean et al. Adrenal apoplexy
Ettema et al. IX. Health effects of exposure to noise, commentary on a research program
Jain et al. Sexual disorders in the elderly.
Dawe et al. Effects of a xanthine derivative, oxpentifylline, on certain psychological parameters of behaviour and performance
GB9617611D0 (en) Treatment of autoimmune disease
Cohen et al. Spatial distribution of signal and adaptive sensitivity in the receptive field surrounds of cat retinal ganglion cells
Wilson THE INTRAVENOUS GLUCOSE TOLERANCE CURVE AS AN INDEX OF LIVER FUNCTION AND LIVER REPLACEMENT THERAPY IN CASES OF HEPATIC INSUFFICIENCY
Regan et al. epic patients. Arch. of Ophth., 1944
Siitonen Hydralazine and oxprenolol in the treatment of hypertension and the effect of these drugs on plasma renin activity
Lee et al. Does sodium restriction lower blood pressure?
Salt-poor AMA Arch. Internal Medicine, Chicago
THOMPSON et al. 874 THE LANCET,] NOTES, SHORT COMMENTS, AND ANSWERS TO CORRESPONDENTS.[APRIL 29, 1922
Cr'uS0X r^ e^? l? gy.? It consisted almost entirely of
BIERMAN INTERNATIONAI, REVIEVV

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 495831

Country of ref document: ES